Does the media refer more to CDXS or PACB?

In the previous week, Codexis had 11 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 13 mentions for Codexis and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 1.30 beat Codexis' score of 0.29 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLP or CDXS more profitable?

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Codexis -39.55% -74.36% -23.58%

Does the media favor SLP or CDXS?

In the previous week, Codexis had 8 more articles in the media than Simulations Plus. MarketBeat recorded 13 mentions for Codexis and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.18 beat Codexis' score of 0.29 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CDXS or LAB more profitable?

Standard BioTools has a net margin of 100.36% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -7.57% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Standard BioTools 100.36% -7.57% -6.14%

Does the media prefer CDXS or LAB?

In the previous week, Codexis had 11 more articles in the media than Standard BioTools. MarketBeat recorded 13 mentions for Codexis and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.63 beat Codexis' score of 0.29 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Standard BioTools 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CDXS or TKNO more profitable?

Alpha Teknova has a net margin of -38.37% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.94% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Alpha Teknova -38.37% -24.94% -16.53%

Which has stronger valuation and earnings, OABI or CDXS?

Codexis has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 29.62 -$64.78M -$0.36 N/A Codexis $70.39M 2.47 -$43.97M -$0.34 N/A

Is OABI or CDXS more profitable?

Codexis has a net margin of -39.55% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Codexis -39.55% -74.36% -23.58%

Does the media favor OABI or CDXS?

In the previous week, OmniAb had 5 more articles in the media than Codexis. MarketBeat recorded 18 mentions for OmniAb and 13 mentions for Codexis. OmniAb's average media sentiment score of 0.69 beat Codexis' score of 0.29 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Codexis (CDXS) Competitors

$1.59 +0.03 (+1.92%)

As of 04:00 PM Eastern

Compare

CDXS vs. PACB, SLP, LAB, TKNO, and OABI

Should you buy Codexis stock or one of its competitors? Codexis's main competitors and comparable companies include Pacific Biosciences of California (PACB), Simulations Plus (SLP), Standard BioTools (LAB), Alpha Teknova (TKNO), and OmniAb (OABI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Codexis compare to Pacific Biosciences of California?

Codexis (NASDAQ:CDXS) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Codexis has higher earnings, but lower revenue than Pacific Biosciences of California. Codexis is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.47	-$43.97M	-$0.34	N/A
Pacific Biosciences of California	$160.01M	2.35	-$546.38M	-$0.43	N/A

In the previous week, Codexis had 11 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 13 mentions for Codexis and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 1.30 beat Codexis' score of 0.29 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.5% of Codexis shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Codexis has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Codexis currently has a consensus price target of $6.50, suggesting a potential upside of 308.81%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 51.52%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Codexis is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Codexis has a net margin of -39.55% compared to Pacific Biosciences of California's net margin of -82.49%. Codexis' return on equity of -74.36% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Summary

Codexis beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Codexis compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Simulations Plus currently has a consensus target price of $17.25, indicating a potential downside of 6.05%. Codexis has a consensus target price of $6.50, indicating a potential upside of 308.81%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Codexis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Simulations Plus has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Codexis has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market.

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Codexis	-39.55%	-74.36%	-23.58%

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Codexis had 8 more articles in the media than Simulations Plus. MarketBeat recorded 13 mentions for Codexis and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.18 beat Codexis' score of 0.29 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Codexis has lower revenue, but higher earnings than Simulations Plus. Codexis is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.69	-$64.72M	$0.40	45.90
Codexis	$70.39M	2.47	-$43.97M	-$0.34	N/A

Summary

Simulations Plus beats Codexis on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Standard BioTools?

Codexis (NASDAQ:CDXS) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Codexis has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Codexis has higher earnings, but lower revenue than Standard BioTools. Codexis is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.47	-$43.97M	-$0.34	N/A
Standard BioTools	$85.33M	3.15	-$74.90M	$0.22	3.11

Standard BioTools has a net margin of 100.36% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -7.57% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Standard BioTools	100.36%	-7.57%	-6.14%

78.5% of Codexis shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Codexis had 11 more articles in the media than Standard BioTools. MarketBeat recorded 13 mentions for Codexis and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.63 beat Codexis' score of 0.29 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Standard BioTools	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 308.81%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 97.22%. Given Codexis' stronger consensus rating and higher possible upside, equities analysts clearly believe Codexis is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Standard BioTools beats Codexis on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Alpha Teknova?

Codexis (NASDAQ:CDXS) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Alpha Teknova has a net margin of -38.37% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.94% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Alpha Teknova	-38.37%	-24.94%	-16.53%

Codexis has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, Codexis had 12 more articles in the media than Alpha Teknova. MarketBeat recorded 13 mentions for Codexis and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.44 beat Codexis' score of 0.29 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Alpha Teknova	Positive

78.5% of Codexis shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alpha Teknova has lower revenue, but higher earnings than Codexis. Alpha Teknova is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.47	-$43.97M	-$0.34	N/A
Alpha Teknova	$40.52M	9.55	-$17.26M	-$0.31	N/A

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 308.81%. Alpha Teknova has a consensus price target of $7.50, indicating a potential upside of 3.88%. Given Codexis' stronger consensus rating and higher possible upside, equities analysts clearly believe Codexis is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Alpha Teknova beats Codexis on 8 of the 15 factors compared between the two stocks.

How does Codexis compare to OmniAb?

OmniAb (NASDAQ:OABI) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

OmniAb has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Codexis has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

OmniAb presently has a consensus price target of $11.00, indicating a potential upside of 187.96%. Codexis has a consensus price target of $6.50, indicating a potential upside of 308.81%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Codexis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Codexis has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	29.62	-$64.78M	-$0.36	N/A
Codexis	$70.39M	2.47	-$43.97M	-$0.34	N/A

Codexis has a net margin of -39.55% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Codexis	-39.55%	-74.36%	-23.58%

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, OmniAb had 5 more articles in the media than Codexis. MarketBeat recorded 18 mentions for OmniAb and 13 mentions for Codexis. OmniAb's average media sentiment score of 0.69 beat Codexis' score of 0.29 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Codexis beats OmniAb on 8 of the 14 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$170.83M	$9.56B	$7.03B	$13.06B
Dividend Yield	N/A	1.46%	2.56%	10.62%
P/E Ratio	-4.68	61.08	270.85	25.39
Price / Sales	2.47	108.12	607.83	92.50
Price / Cash	N/A	26.11	28.87	38.47
Price / Book	2.84	5.16	11.09	6.51
Net Income	-$43.97M	$56.67B	$3.45B	$347.22M
7 Day Performance	6.00%	0.63%	0.74%	1.51%
1 Month Performance	-29.02%	3.51%	2.15%	2.74%
1 Year Performance	-47.18%	18.41%	63.00%	21.07%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	3.2682 of 5 stars	$1.59 +1.9%	$6.50 +308.8%	-48.2%	$170.83M	$70.39M	N/A	250	Earnings Report Analyst Downgrade
PACB Pacific Biosciences of California	1.7503 of 5 stars	$1.17 -10.4%	$1.83 +57.4%	-12.2%	$403.78M	$160.01M	N/A	730	High Trading Volume
SLP Simulations Plus	1.0246 of 5 stars	$18.34 +0.1%	$17.25 -5.9%	+28.9%	$370.52M	$82.06M	45.85	160	Positive News Short Interest Increase
LAB Standard BioTools	2.9891 of 5 stars	$0.80 +2.0%	$1.35 +68.7%	-42.1%	$306.09M	$85.33M	3.64	620
TKNO Alpha Teknova	1.8805 of 5 stars	$6.53 +16.4%	$7.00 +7.2%	+55.4%	$300.77M	$40.52M	N/A	240	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. PACB, SLP, LAB, TKNO, and OABI

How does Codexis compare to Pacific Biosciences of California?

Summary

How does Codexis compare to Simulations Plus?

Summary

How does Codexis compare to Standard BioTools?

Summary

How does Codexis compare to Alpha Teknova?

Summary

How does Codexis compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. PACB, SLP, LAB, TKNO, and OABI

How does Codexis compare to Pacific Biosciences of California?

Which has higher earnings & valuation, CDXS or PACB?

Does the media refer more to CDXS or PACB?

Do insiders & institutionals believe in CDXS or PACB?

Which has more risk and volatility, CDXS or PACB?

Do analysts rate CDXS or PACB?

Is CDXS or PACB more profitable?

Summary

How does Codexis compare to Simulations Plus?

Do analysts rate SLP or CDXS?

Which has more volatility and risk, SLP or CDXS?

Is SLP or CDXS more profitable?

Do institutionals and insiders believe in SLP or CDXS?

Does the media favor SLP or CDXS?

Which has better earnings and valuation, SLP or CDXS?

Summary

How does Codexis compare to Standard BioTools?

Which has more volatility and risk, CDXS or LAB?

Which has better valuation & earnings, CDXS or LAB?

Is CDXS or LAB more profitable?

Do insiders and institutionals believe in CDXS or LAB?

Does the media prefer CDXS or LAB?

Do analysts prefer CDXS or LAB?

Summary

How does Codexis compare to Alpha Teknova?

Is CDXS or TKNO more profitable?

Which has more volatility and risk, CDXS or TKNO?

Does the media prefer CDXS or TKNO?

Do insiders and institutionals believe in CDXS or TKNO?

Which has better valuation & earnings, CDXS or TKNO?

Do analysts prefer CDXS or TKNO?

Summary

How does Codexis compare to OmniAb?

Which has more volatility & risk, OABI or CDXS?

Do analysts prefer OABI or CDXS?

Which has stronger valuation and earnings, OABI or CDXS?

Is OABI or CDXS more profitable?

Do insiders and institutionals believe in OABI or CDXS?

Does the media favor OABI or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools